Granulocyte colony-stimulating factor: Difference between revisions
imported>Howard C. Berkowitz (New page: '''Granulocyte colony-stimulating factor (G-CSF)''' is a glycoprotein of MW 25 kDa, which stimulate the production of neutrophils and their precursors, and is used to treat [[neutrope...) |
imported>Howard C. Berkowitz No edit summary |
||
| Line 1: | Line 1: | ||
'''Granulocyte colony-stimulating factor (G-CSF)''' is a glycoprotein of MW 25 kDa, which stimulate the production of [[neutrophil]]s and their precursors, and is used to treat [[neutropenia]]. | '''Granulocyte colony-stimulating factor (G-CSF)''' is a glycoprotein of MW 25 kDa, which stimulate the production of [[neutrophil]]s and their precursors, and is used to treat [[neutropenia]]. In the United States, it is approved as Neupogen. | ||
It is a [[glycoprotein]] containing disulfide bonds, which has a molecular | It is a [[glycoprotein]] containing disulfide bonds, which has a molecular weight of 25 kilodalton (kDa) Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.<ref>{{MeSH}}</ref> | ||
It is not the same agent as [[granulocyte-macrophage colony-stimulating factor]] (GM-CSF), the synthetic version of which is filagastrim. | It is not the same agent as [[granulocyte-macrophage colony-stimulating factor]] (GM-CSF), the synthetic version of which is filagastrim. | ||
==Medical indications== | |||
Labeled as approved uses by the U.S. [[Food and Drug Administration]]:<ref>{{citation | |||
| url = http://www.medscape.com/druginfo/dosage?cid=med&drugid=9370&drugname=Neupogen+Inj&monotype=default | |||
| title = Neupogen Inj: Doses and Indications | |||
| publisher = American Society for Health System Pharmacists/Medscape}}</ref> Chemotherapy-induced neutropenia, [[congenital neutropenia]], [[cyclic neutropenia]], [[idiopathic neutropenia]], [[Neutropenia Secondary to AML Treatment]], Prevention of Neutropenia from Cancer Chemotherapy, progenitor cell Enhancement, [[severe chronic neutropenia]] | |||
Unlabeled Uses: AIDS-associated neutropenia, drug-induced neutropenia, [[myelodysplastic syndrome]], [[myeloid engraftment enhancement]], Neutropenic Disorder | |||
==References== | |||
{{reflist}} | |||
Revision as of 12:52, 30 July 2010
Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein of MW 25 kDa, which stimulate the production of neutrophils and their precursors, and is used to treat neutropenia. In the United States, it is approved as Neupogen.
It is a glycoprotein containing disulfide bonds, which has a molecular weight of 25 kilodalton (kDa) Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.[1]
It is not the same agent as granulocyte-macrophage colony-stimulating factor (GM-CSF), the synthetic version of which is filagastrim.
Medical indications
Labeled as approved uses by the U.S. Food and Drug Administration:[2] Chemotherapy-induced neutropenia, congenital neutropenia, cyclic neutropenia, idiopathic neutropenia, Neutropenia Secondary to AML Treatment, Prevention of Neutropenia from Cancer Chemotherapy, progenitor cell Enhancement, severe chronic neutropenia
Unlabeled Uses: AIDS-associated neutropenia, drug-induced neutropenia, myelodysplastic syndrome, myeloid engraftment enhancement, Neutropenic Disorder
References
- ↑ Anonymous (2024), Granulocyte colony-stimulating factor (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Neupogen Inj: Doses and Indications, American Society for Health System Pharmacists/Medscape